Feed / VCYT

Veracyte, Inc. Common Stock

VCYT

Healthcare · 41.75 -1.0% today

Partial group confirmationMarket checked 20 Aug, 15:55 GMT-4

Jodie situation report

Veracyte, Inc. Common Stock's move is being confirmed by its market group.

VCYT accounts for 1.8% of the group's measured movement across 4.5 effective names. raw member direction is mixed; 0 of 10 session-normalized paths align to the mixed. Capital-flow agreement is 53%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveIndependent mover#7 of 10 by movement share
Group movement share1.8%Absolute path energy—not portfolio weight
Relative path-0.47%mixed
Effective breadth4.5 / 10balanced
Relative alignment0/10mixed path · 0 counter-moving
Capital-flow agreement53%not yet clean
SEQUENCE READ

ADPT, MRNA, CORT moved materially before VCYT. VCYT crossed its material path threshold at 10:10 ET, 30 minutes after the first measured mover.

What changed
  • Revenue increased 21.5% versus the comparable filing period.
EVIDENCE COVERAGE

5 of 10 members in Cancer Diagnostics are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 7 of 10 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as MYGN begins moving with the group.

Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.

Watch this read

Who this business touches

The relationships behind VCYT

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CAICaris Life Sciences, Inc.competitorFeb 26, 2026

As we expand our portfolio of tests, including into the MRD space, we may also face competition from companies informing treatment decisions such as Natera, Inc., Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Neogenomics, Inc…

DGXQuest Diagnostics IncorporatedcompetitorFeb 26, 2026

As we expand our portfolio of tests, including into the MRD space, we may also face competition from companies informing treatment decisions such as Natera, Inc., Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Neogenomics, Inc…

Depended on by

PSNLPersonalis, Inc.competitorMay 7, 2026

Some of our present or potential competitors, including Adela, Inc., Caris Life Sciences, Inc., DELFI Diagnostics, Inc., Exact Sciences Corporation, which was acquired by Abbott Laboratories, Inc., in March 2026, Foresight Diagnostics Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

VCYT is currently a Participant in the organic co-movement group Cancer Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.